sotatercept + prednisone

Sotatercept + prednisone is a combination of two drugs used in clinical settings. Sotatercept is a first-in-class biologic agent that acts as an activin signaling inhibitor targeting the bone morphogenetic protein/activin pathway. It is primarily indicated for the treatment of pulmonary arterial hypertension (PAH), where it improves exercise capacity and reduces clinical worsening when added to background therapy[3][4][6]. Sotatercept was developed by Merck and is marketed under the brand name WINREVAIR[3][7]. Prednisone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties, widely used for various inflammatory and autoimmune conditions. The combination may be considered in specific clinical scenarios where both agents are indicated; however, there are no major studies or approvals specifically for their combined use as a fixed-dose product.

Other names

sotatercept and prednisone